Health 2.0 Europe 2011

27 - 28 October 2011, Berlin, Germany.
Following the success of the first edition in Paris in April 2010, the 2nd annual Health 2.0 Europe in Berlin has been announced. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offerings with some American input too. Co-hosted with K.I.T. Group, the 2nd edition will reconvene all the leaders and stakeholders in web 2.0 health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

2011 Program Highlights
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. Health 2.0 Europe will be seeing what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in the lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions. 2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion and wellness 2.0
  • Behavior change tools
  • Privacy, data, trust
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Mobile devices and smart phones

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Make it your event. Get involved now!
To submit a topic, a speaker, or a start up for the Launch! session, or to inquire about becoming a partner of the event, please contact:

Pascal Lardier, Director, International conferences
This email address is being protected from spambots. You need JavaScript enabled to view it.

Historical Venue
After the Cité Internationale in April 2010, the 2011 event is taking us to yet another historical landmark: the Langenbeck-Virchow building of the Charité Hospital and University of Medicine.

It was built in 1914-15 to be the seat of the German Surgical Society and the Berlin Medical Association. From 1950 to 1976, the Parliament of East Germany was constituted in its auditorium and started convening in the Great Hall. After the collapse of Berlin Wall in 1989 and a long legal conflict, the German Surgical Society and the Berlin Medical Association returned to their home.

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...